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Abstract We studied occurrence, presentation, disease course,
effect of adjunctive dexamethasone, and prognosis of bacterial
meningitis in patients using immunosuppressive medication.
Patients were selected from our nationwide, prospective cohort
on community-acquired bacterial meningitis performed from
March 1, 2006 through October 31, 2014. Eighty-seven of
1447 episodes (6%) of bacterial meningitis occurred in patients
using immunosuppressive medication, and consisted of corti-
costeroids in 82 %. Patients with bacterial meningitis using
immunosuppressive medication were less likely to present with
headache (P = 0.02) or neck stiffness (P = 0.005), as compared
those not on immunosuppressive medication. In 46 % of epi-
sodes CSF leukocyte count was below 1000/mm3. CSF cul-
tures revealed S. pneumoniae in 41 % and L. monocytogenes
in 40 % of episodes. Outcome was unfavorable in 39 of 87
episodes (45 %) and death occurred in 22 of 87 episodes
(25 %). Adjunctive dexamethasone was administered in 52 of
87 (60 %) episodes, and mortality tended to be lower in those
on adjunctive dexamethasone therapy as compared to those
without dexamethasone therapy (10 of 52 [19 %] vs 12 of 35
[34 %], P = 0.14). We conclude that bacterial meningitis in
patients using immunosuppressive medication is likely to pres-
ent with atypical clinical and laboratory features, and is often
caused by atypical bacteria, mainly L. monocytogenes.
Adjunctive dexamethasone is widely prescribed in these pa-
tients and was not associated with harm in this study.
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Introduction
Community-acquired bacterial meningitis is a severe infec-
tious disease with high morbidity and mortality rates
(Brouwer et al. 2010), and is most commonly caused by
Streptococcus pneumoniae (van de Beek et al. 2004b).
Acquired immunodeficiency previously has been associated
with an increased risk of bacterial meningitis (Adriani et al.
2013; van Veen et al. 2016; Weisfelt et al. 2010). One of the
most common acquired conditions causing immunodeficiency
is the use of immunosuppressive medication, including corti-
costeroids. The proposed mechanisms by which corticoste-
roids cause immunosuppression are decreased production,
function and migration of inflammatory cells and decreased
antibody production (Fardet et al. 2007). A meta-analysis
showed an increased risk of systemic infections for patients
using corticosteroids compared to patients not using cortico-
steroids, with a relative risk of 1.6 (95 % confidence interval
[CI] 1.3–1.9), although it remains unclear whether corticoste-
roids or the underlying disease increased the risk of infection
(Stuck et al. 1989). The use of immunosuppressive medication
has been reported to be an important predisposing factor for
infections with Listeria monocytogenes (Yildiz et al. 2007).
Glucocorticoids can also mask the symptoms of infection and
therefore delay treatment because patients present at an ad-
vanced stage of disease (Fardet et al. 2007).
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Little is known about the clinical course of bacterial men-
ingitis in patients using immunosuppressive medication.
Randomized clinical trials have evaluated the efficacy of
adjunctive corticosteroid therapy in community-acquired bac-
terial meningitis (Brouwer et al. 2015; de Gans and van de
Beek 2002; van de Beek et al. 2004a; van de Beek et al. 2010).
As a result, adjunctive dexamethasone has been incorporated
in treatment guidelines for bacterial meningitis (Tunkel et al.
2004; van de Beek et al. 2012; van de Beek et al. 2006).
However, patients on immunosuppressive medication were
excluded from the clinical trial and guidelines generally dis-
courage the use of adjunctive dexamethasone in patients using
immunosuppressive medication (Tunkel et al. 2004; van de
Beek et al. 2012; van de Beek et al. 2006).
We studied clinical features and outcome of community-
acquired bacterial meningitis in adults using immunosuppres-
sive medication identified in a nationwide prospective cohort
study, and evaluated the effect of adjunctive dexamethasone in
this particular subgroup of patients.
Methods
We conducted a nationwide, prospective cohort study on
community-acquired bacterial meningitis. Methods have been
described in detail previously (Bijlsma et al. 2016). From this
cohort we selected all patients who were reported to use immu-
nosuppressive medication. Immunosuppressive medication
were classified in fourmain groups: glucocorticoids, small mol-
ecule drugs (e.g. cyclosporine, tacrolimus, everolimus, myco-
phenolate mofetil, azathioprine), protein drugs (e.g. horse or
rabbit antithymocyte globulin, rituximab) and cytostatic drugs
(Halloran 2004). Between March 2006 and October 2014, pa-
tients with bacterial meningitis over 16 years old were included.
Bacterial meningitis was defined as a positive cerebrospinal
fluid (CSF) culture or as a positive blood culture with a relevant
pathogen, positive PCR or antigen test in cerebrospinal fluid, in
combination with at least one CSF finding predictive of bacte-
rial meningitis consisting of a CSF leukocyte count >2000
cells/mm3, polymorphonuclear leukocyte count >1180 cells/
mm3, glucose level < 1.9 mmol/L, protein level > 2gL, or
CSF/blood glucose ratio < 0.23 (Spanos et al. 1989).
Patients with a neurosurgical device, neurosurgical operation
or procedure and patients with neurotrauma within one month
of the onset of meningitis were excluded from the cohort. Data
on patient history, symptoms and signs on admission, laborato-
ry findings, radiologic examination, treatment, and outcome
were prospectively collected by means of a case record form
(CRF). Dosage of immunosuppressive medication was collect-
ed retrospectively from the discharge letters. For corticosteroids
the dosage was calculated as the daily prednisolone equivalent
dose. To this end dosage of hydrocortisone was divided by 4
and dosage of dexamethasone was multiplied by 6.7. All
patients underwent neurologic examination at hospital dis-
charge, and outcome was graded using the Glasgow Outcome
Scale (GOS). A favorable outcome was defined as a score of 5,
and an unfavorable outcome was defined as a score of 1 to 4.
The study was approved by the ethical committee of the
Academic Medical Center.
Statistical analyses were performed with the use of SPSS
statistical software, version 22 (SPSS Inc.). For numerical and
ordinal data the student t-test or Mann-Whitney U test were
used. For categorical data the Fisher exact test was used.
Logistic regression was used to examine the association be-
tween potential predictors and the likelihood of an unfavor-
able outcome and of death. Odds ratios (OR) and 95 % con-
fidence intervals were used to quantify the strength of these
associations. Possible predictors of an unfavorable outcome
and death were chosen on the basis of previous research
(Koopmans et al. 2013; van de Beek et al. 2004b). All tests
were 2-tailed, and p < 0.05 was considered significant.
Results
Patients and Immunosuppressive Medication
A total of 1447 episodes of bacterial meningitis were included
in the cohort between March 2006 and October 2014.
Medication on admission was known for 1435 patients
(99 %). In 87 of these episodes (6 %) in 86 patients, patients
were reported to use immunosuppressive medication.
The immunosuppressive treatment consisted of glucocorti-
coids in 71 episodes and was used as monotherapy in 45 epi-
sodes, and in combination with other immunosuppressive treat-
ment in 26 episodes (Table 1). Auto-immune diseases (e.g. rheu-
matoid arthritis, ulcerative colitis) in 38 of 87 episodes (44 %)
and cancer in 21 of 87 episodes (24 %) were the most frequent
indications for immunosuppressive therapy. For corticosteroids,
the median daily dosage was 20 mg prednisone (interquartile
range [IQR] 7–30mg). The median age of patients using immu-
nosuppressive medication at the time of the episode of bacterial
meningitis was 65 years (range 19–91 years; Table 2). Other co-
existing conditions increasing the risk of meningitis were diabe-
tes mellitus (in 16 episodes), alcoholism (in six episodes), and
splenectomy (in four episodes). Distant foci of infection were
identified in 25 of 82 episodes (31 %). One patient had a recur-
rence of bacterial meningitis during the study period and had a
medical history of kidney transplantation.
Clinical Features
Headache occurred in 56 of 78 episodes (72 %), neck stiffness
in 51 of 85 episodes (60 %), fever in 64 of 86 episodes (74 %),
and a change in mental status (defined by a GOS score below
14) in 61 of 87 of episodes (70 %). The classic triad of fever,
neck stiffness, and a change in mental status was present in 31
of 86 of episodes (36 %). In 7 of 87 of episodes (8 %), fever,
neck stiffness, and a change in mental status were all absent.
Headache and neck stiffness were less often present in patients
using immunosuppressive medication compared to patients
not using immunosuppressive medication (respectively 56 of
78 [72%] vs 961 of 1161 [83%], P = 0.02 and 51 of 85 [60%]
vs 945 of 1261 [75 %], P = 0.005; Table 2).
A lumbar puncturewas performed in all patients. Independent
predictors of bacterial meningitis (Spanos et al. 1989) were pres-
ent in 72 of 87 (83%) patients.MedianCSF leukocyte count was
1368 cells/mm3 (IQR 443–3166 cells/mm3). Patients using im-
munosuppressive medication had lower CSF leukocyte count as
compared to bacterial meningitis patients not using immunosup-
pressive medication (1368 cells/mm3 vs 2560 cells/mm3,
P = 0.003) and more often a leukocyte count <1000 cells/mm3
(39 of 85 [46 %] vs. 401 of 1234 [32 %], P = 0.02).
Blood chemistry tests showed patients using immunosup-
pressive medication often had no or only mildly elevated
whole blood leukocyte counts (median 13.9 × 109/L [IQR
9.1–20.0 × 109/L]). In 30 of 86 of episodes (35 %) patients
had blood leukocyte counts of <11.0 × 109/L.
Neuroimaging (computed tomography) was performed on
admission in 75 of 87 episodes (86 %) concerning patients
using immunosuppressive medication, and showed abnormal-
ities in 26 patients: brain abscess in two, sinus or mastoid
opacification in nine, generalized brain edema in eight, a
hypodense lesion presumed to be infarction in three, subdural
effusion in two, and hydrocephalus in one. Both patients with
brain abscess had listerial meningitis. Of the patients with a
brain abscess one presented with aphasia and confusion
while the other had no focal neurologic deficits.
CSF cultures revealed S. pneumoniae in 36 episodes (41 %),
L. monocytogenes in 35 episodes (40 %), Haemophilus
influenzae in six episodes (7 %), and Neisseria meningitidis in
two episodes (2%). One patient had a negative CSF culture, but
had a positive antigen test for S. pneumoniae as causative or-
ganism. Other causative organisms were Escherichia coli in
two episodes andNocardia farcinica, Streptococcus anginosus,
Streptococcus mitis, and Pseudomonas aeruginosa in one epi-
sode each. Pneumococcal and meningococcal meningitis oc-
curred less often in patients using immunosuppressive medica-
tion compared to those who did not (37 of 87 [43 %] vs. 981 of
1348 [73 %], P = <0.0001 and 2 of 87 [2 %] vs. 147 of 1348
[11 %], P = 0.006), whilst listerial meningitis was encountered
more frequently (35 of 87 [40 %] vs. 43 of 1348 [3 %],
P < 0.0001). Inadequate initial antimicrobial therapy was
started in seven of 86 patients (8 %) and consisted of failure
to start amoxicillin in patients with L. monocytogenesmeningi-
tis in five patients.
Outcome
Outcome was unfavorable in 39 of 87 episodes (45 %) of
bacterial meningitis in patients using immunosuppressive
medication and in 22 of 87 episodes (25 %) the patient died.
The rate of unfavorable outcome was similar between patients
with and without immunosuppressive medication (39 of 87
[45 %] vs. 495 of 1348 [37 %], P = 0.14) but mortality was
higher in those using immunosuppressive medication (22 of
87 [25 %] vs. 219 of 1348 [16 %], P = 0.04). In a univariable
analysis, the use of immunosuppressive medication was asso-
ciated with death (OR 1.75; 95%CI 1.05–2.89, P = 0.03). In a
multivariable analysis adjusting for age (categories: < 40, 40–
70, > 70 years), otitis or sinusitis, diabetes mellitus, neck stiff-
ness, score on GOS, CSF leukocyte (<1000 cells/mm3), CSF
protein (g/l), thrombocyte count (< 150 × 1012/L), C-reactive
protein (mg/l) and L. monocytogenes, the use of immunosup-
pressive medication was no longer associated with death (OR
0.94, 95 % CI 0.46–1.93, P = 0.86).
Table 1 Groups of
immunosuppressive agents and
categories of indication
Immunosuppressive medication n/N (%) Indication n/N (%)
Glucocorticoids 45/87 (52) Auto-immune disease 38/87 (44)
Glucocorticoids + small molecule drugs 13/87 (15) Rheumatoid arthritis 12/38 (32)
Glucocorticoids + cytostatic drugs 9/87 (10) Ulcerative colitis 7/38 (18)
Glucocorticoids + protein drugs 3/87 (3) Polymyalgia rheumatica 5/38 (13)
Glucocorticoids + SMD + PD 1/87 (1) Auto-immune hepatitis 3/38 (8)
Cytostatic drugs 9/87 (10) Systemic lupus erythematosus 3/38 (8)
Cytostatic drugs + protein drugs 1/87 (1) Other auto-immune disease 8/38 (21)
Small molecule drugs 6/87 (7) Cancer 21/87 (24)
Median dosage prednisone in mga 20 (7–30)b Renal transplantation 6/87 (7)
Other 11/87 (13)
Unknown 4/87 (5)
PD protein drugs, SMD small molecule drugs
a Known in 46 of 71 patients
b Interquartile range
Neurological sequelae occurred in 18 of 53 surviving pa-
tients (34 %) and consisted mostly of cognitive impairment in
eight of 52 episodes (15 %) and cranial nerve palsies in eight
of 53 episodes (15 %). The use of immunosuppressive medi-
cation did not influence the risk of sequelae (OR 1.09; 95 %
CI 0.62–1.91; P = 0.76).
Adjunctive Dexamethasone Therapy
In 52 of 87 episodes (60 %), patients were treated with ad-
junctive dexamethasone according to guideline recommenda-
tions (10 mg four times per day for 4 days, administered
before or together with the antibiotics). In three episodes dexa-
methasone was started but discontinued because
L. monocytogenes was identified as the pathogen. Baseline
characteristics between those who did and did not receive
dexamethasone were similar. Unfavorable outcome was ob-
served in 21 of 52 episodes (40 %) of patients treated with
adjunctive dexamethasone and in 18 of 35 episodes (51%) not
treated with adjunctive dexamethasone (P = 0.289). There was
a trend towards protection against death for patients treated
with dexamethasone (10 of 52 [19 %] vs 12 of 35 [34 %],
P = 0.14). In an univariable analysis, for patients using immu-
nosuppress ive medicat ion the OR of adjunct ive
Table 2 Comparison between patients with and without immunosuppressive medicationa
Characteristic immunosuppressive medication + immunosuppressive medication – P-value
Age (years) 65 (19–91) 61 (17–94) 0.002
Female 30/87 (34) 674/1348 (50) 0.006
Symptoms and signs on admission
Headache 56/78 (72) 962/1161 (83) 0.02
Neck stiffness 51/85 (60) 945/1261 (75) 0.005
Triad of fever, neck stiffness, and change in mental status 31/86 (36) 543/1283 (42) 0.26
Absence of fever, neck stiffness, and change in mental status 7/87 (8) 43/1334 (3) 0.03
Predisposing factorsb 23/87 (26) 266/1348 (20) 0.13
Distant focus of infection 25/82 (30) 581/1289 (45) 0.01
Blood chemistry testsc
Leukocyte count (×109/L) 13.9 (0.1–45.6) 17.1 (0.1–99.8) 0.0001
C-reactive protein (mg/L) 163 (3–500) 192 (0–752) 0.28
Indexes of inflammation in CSFd
Leukocyte count (cells/mm3) 1368 (5–46,500) 2560 (0–463,149) 0.003
Leukocyte count <1000 cells/mm3 39/85 (46) 401/1234 (32) 0.02
Protein (g/L) 3.00 (0.45–11.0) 4.00 (0.02–50.0) P < 0.0005
CSF/blood glucose ratio 0.17 (0.0–0.89) 0.04 (0.0–1.67) 0.003
Causative organism
Streptococcus pneumoniae 37/87 (43) 981/1348 (73) P < 0.0001
Listeria monocytogenes 35/87 (40) 43/1348 (3) P < 0.0001
Haemophilus influenzae 6/87 (7) 44/1348 (3) 0.12
Neisseria meningitidis 2/87 (2) 147/1348 (11) 0.006
Othere 7/87 (8) 133/1348 (10) 0.71
Outcome
Unfavorable outcome 39/87 (45) 495/1348 (37) 0.14
Mortality 22/87 (25) 219/1348 (16) 0.04
Neurological sequelae 18/53 (34) 360/997 (36) 0.88
CSF cerebrospinal fluid
a Data are presented as n/N (%), or median (range)
b Other than immunosuppressive medication
c Leukocyte count was known in 86 and 1327 episodes and C-reactive protein in 85 and 1283
d CSF leukocyte count was known in 85 and 1234 episodes, CSF protein levels in 85 and 1275 episodes, and CSF blood to glucose ratio in 77 and 1249
episodes
e See Table 2 for details of causative organisms
dexamethasone treatment for death was 0.46 (95 % CI 0.17–
1.22, P = 0.12). The effect size was not influenced by known
pred i c t o r s o f dea th – age , s co r e on GOS and
L. monocytogenes as causative organism – in a multivariable
analysis (OR 0.46; 95 % CI 0.16–1.31; P = 0.15). No adverse
events related to the treatment with adjunctive dexamethasone
were reported.
Discussion
Patients with bacterial meningitis using immunosuppres-
sive medication are less likely to present with typical
clinical characteristics of meningitis, such as headache
and neck stiffness, and have less marked CSF white cell
counts. About half of patients had a CSF white cell
count below 1000 per mm3; however, about 80 % had
one of more independent CSF predictors of bacterial
meningitis (Spanos et al. 1989). Cultures often reveal
L. monocytogenes (40 %) or other atypical causative
organisms, such as Nocardia or Pseudomonas. To pre-
vent diagnostic and therapeutic delay, a low threshold
should be kept for performing a lumbar puncture in
patients using immunosuppressive medication, even
those with a low clinical suspicion of bacterial menin-
gitis. Adjunctive dexamethasone is widely prescribed for
patients using immunosuppressive medication who are
admitted with bacterial meningitis and is not associated
with harm.
The association of Listeria infections with immunosup-
pressive medication, and glucocorticoids especially, has been
well recognized by earlier studies (Hooper et al. 1982; Yildiz
et al. 2007). The predilection for immunocompromised hosts
may be explained by the intracellular life cycle of
L. monocytogenes by which it avoids host bactericidal mech-
anisms. Resistance to infection is predominantly mediated by
cellular immunity and their elimination requires T lympho-
cytes mediated cytotoxicity (Horta-Baas et al. 2013).
Guidelines advise the use of a third generation cephalosporin
combined with ampicillin or amoxicillin if L. monocytogenes
is suspected (Chaudhuri et al. 2008; Tunkel et al. 2004). Based
on the high frequency of L. monocytogenes as causative or-
ganism in patients using immunosuppressivemedication iden-
tified in our cohort, empiric treatment for patients using im-
munosuppressive medication should be broad and include
ampicillin or amoxicillin for listeria coverage in combination
with an extended spectrum cephalosporin.
Adjunctive dexamethasone did not influence rates of unfa-
vorable outcome. However, there was trend towards protec-
tion against death for patients treated with dexamethasone.
This observed effect size was similar to that of the total pop-
ulation of bacterial meningitis patients and was not influenced
by known other risk factors of mortality (de Gans and van de
Beek 2002). Patients treated with adjunctive dexamethasone
did not experience a higher rate of dexamethasone-related
complications such as hyperglycemia requiring insulin, gastric
bleeding, and herpes simplex infection. Randomized con-
trolled trials on the effect of adjunctive dexamethasone in
bacterial meningitis either do not report on the use of cortico-
steroids or immunosuppressive medication (de Gans and van
de Beek 2002; Molyneux et al. 2002; Nguyen et al. 2007), or
have glucocorticoids or immunosuppressive medication as an
exclusion criterion (Peltola et al. 2007; Scarborough et al.
2007). With the number of patients included in this analysis
we lack power to identify a significant association of dexa-
methasone, but we found a similar effect as was identified in
previous studies. Based on these findings the use of adjunctive
dexamethasone should be considered in patients using immu-
nosuppressive medication.
Our study has limitations. The observational design of the
study is sensitive to the introduction of confounding factors,
which hinder the evaluation of dexamethasone effectiveness.
Other limitations of this study were that only patients with
culture-proven meningitis were included in our cohort study.
Not all patients with suspected bacterial meningitis may un-
dergo a lumbar puncture, e.g. patients with coagulopathy due
to sepsis or those with space-occupying lesions on cranial
imaging. These patients were not included in our cohort. As
the use of immunosuppressive medication is a risk factor for
brain abscess, we could have missed cases of bacterial men-
ingitis in patients use of immunosuppressive medication
(Selby et al. 1997).
In conclusion, patients with bacterial meningitis using im-
munosuppressive medication are less likely to present with
typical clinical characteristics of meningitis and have less
marked CSF abnormalities. Cultures often reveal
L. monocytogenes (40 %) or other atypical causative organ-
isms. Adjunctive dexamethasone is widely prescribed for pa-
tients using immunosuppressive medication who are admitted
with bacterial meningitis and was not found to be associated
with harm, although studies in larger sample size are needed to
validate these findings.
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